Nexstim Plc · OMXHEX:NXTMH
Nexstim — H2 2020 Earnings Presentation
7 slides from Nexstim's earnings presentation, Feb 26, 2021
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CEO | Nexstim Plc Joonas Juokslahti | CFO | Nexstim Plc Nexstim Plc H2 2020 & Full Year 2020 Financial Results Webinar, 26 February 2021 Nexstim Plc
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim Business Update H2 2020
Nexstim Business Update H2 2020 Business Operations • Continued to minimize the effect of COVID-19 pandemic as well as focusing on generating profitable revenue growth • Considering the difficult business environment, excellent progress with ‒ 9 new NBS Systems sold (3 in the US and 6 in Europe & RO
Slide 4: FY2020 Key Financials
FY2020 Key Financials Key Figures of the Group Total Net Sales increased by +23% • NBT Net Sales 2.0M€ +28% EUR in thousands • NBS Net Sales 2.2M€ +19% 1-12/2020 1-12/2019 12 months 12 months Recurring Revenue EUR 2.4M (+32%) Net sales 4,114.0 3,348.1 Personnel Expenses decreased by -21% Personnel e
Slide 5: Key Strategic Objectives for Year 2021
Key Strategic Objectives for Year 2021 Business Operations 1 Focus on achieving profitable revenue growth and strict management of operating expenses Report first results from the two new pilot studies in treating severe depression and/or chronic pain patients with accelerated 2 therapy treatment pr
Slide 6: Nexstim has a unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 7: Thank you!
Thank you! Nexstim Plc Public Presentation 7